Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001304887 | SCV001494192 | uncertain significance | Microcephaly-intellectual disability-sensorineural hearing loss-epilepsy-abnormal muscle tone syndrome | 2022-09-07 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 502 of the SPATA5 protein (p.Pro502Leu). This variant is present in population databases (rs759111245, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with SPATA5-related conditions. ClinVar contains an entry for this variant (Variation ID: 1007666). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Prevention |
RCV003433105 | SCV004116875 | uncertain significance | AFG2A-related disorder | 2022-11-15 | criteria provided, single submitter | clinical testing | The AFG2A c.1505C>T variant is predicted to result in the amino acid substitution p.Pro502Leu. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0099% of alleles in individuals of South Asian descent in gnomAD (http://gnomad.broadinstitute.org/variant/4-123868434-C-T). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |